Amarin Accelerates Timeline For NDA Filing Of AMR101
Positive results from a Phase III trial of Amarin Corporation's triglyceride-lowering drug AMR101 will allow the company to submit its NDA to FDA in 2011, a year ahead of schedule.
Positive results from a Phase III trial of Amarin Corporation's triglyceride-lowering drug AMR101 will allow the company to submit its NDA to FDA in 2011, a year ahead of schedule.